PHAT vs. ORIC, OCUL, NKTX, ARQT, INVA, GERN, BHC, VERA, DCPH, and MRVI
Should you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include ORIC Pharmaceuticals (ORIC), Ocular Therapeutix (OCUL), Nkarta (NKTX), Arcutis Biotherapeutics (ARQT), Innoviva (INVA), Geron (GERN), Bausch Health Companies (BHC), Vera Therapeutics (VERA), Deciphera Pharmaceuticals (DCPH), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical preparations" industry.
ORIC Pharmaceuticals (NASDAQ:ORIC) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
In the previous week, Phathom Pharmaceuticals had 7 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 9 mentions for Phathom Pharmaceuticals and 2 mentions for ORIC Pharmaceuticals. ORIC Pharmaceuticals' average media sentiment score of 0.31 beat Phathom Pharmaceuticals' score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.
95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 5.6% of ORIC Pharmaceuticals shares are held by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
ORIC Pharmaceuticals currently has a consensus price target of $20.00, indicating a potential upside of 127.01%. Phathom Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 104.27%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe ORIC Pharmaceuticals is more favorable than Phathom Pharmaceuticals.
Phathom Pharmaceuticals received 25 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. Likewise, 68.57% of users gave Phathom Pharmaceuticals an outperform vote while only 66.20% of users gave ORIC Pharmaceuticals an outperform vote.
ORIC Pharmaceuticals' return on equity of 0.00% beat Phathom Pharmaceuticals' return on equity.
ORIC Pharmaceuticals has higher earnings, but lower revenue than Phathom Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ORIC Pharmaceuticals has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
Summary
Phathom Pharmaceuticals beats ORIC Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Phathom Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phathom Pharmaceuticals Competitors List
Related Companies and Tools
